| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 31 | 29 | 9 | 19 | 12 | 16 | 17 | 13 | 11 | 19 | 21 | 21 | 21 | 24 | 36 | 37 | 34 | 31 | 31 | 47 | 37 | 42 | 35 | 45 | 36 | 53 | 58 | 63 | 46 | 56 |
| Expenses | 25 | 22 | 12 | 16 | 11 | 14 | 14 | 14 | 11 | 15 | 17 | 20 | 19 | 20 | 34 | 32 | 30 | 27 | 26 | 39 | 30 | 33 | 30 | 38 | 32 | 41 | 47 | 47 | 40 | 44 |
| EBITDA | 6 | 6 | -3 | 2 | 1 | 2 | 2 | -1 | -1 | 3 | 3 | 2 | 2 | 4 | 2 | 5 | 4 | 4 | 5 | 7 | 7 | 9 | 5 | 8 | 4 | 11 | 11 | 16 | 6 | 12 |
| Operating Profit % | 11 % | 17 % | -42 % | 15 % | -7 % | 11 % | 10 % | -20 % | -11 % | 16 % | 15 % | 2 % | 5 % | 16 % | 2 % | 14 % | 10 % | 13 % | 13 % | 14 % | 17 % | 21 % | 7 % | 16 % | 5 % | 13 % | 16 % | 24 % | 8 % | 10 % |
| Depreciation | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 0 | 1 | 2 | 2 | 1 |
| Profit Before Tax | 5 | 6 | -4 | 1 | 0 | 2 | 2 | -2 | -2 | 3 | 3 | 1 | 1 | 3 | 2 | 4 | 3 | 2 | 3 | 5 | 5 | 7 | 3 | 5 | 2 | 10 | 8 | 14 | 4 | 9 |
| Tax | 1 | 2 | 1 | 1 | 0 | 0 | 1 | -0 | -0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | -0 | 1 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 3 | 4 | 1 | 1 |
| Net Profit | 4 | 4 | -5 | 1 | -0 | 1 | 1 | -1 | -1 | 2 | 2 | 1 | 1 | 3 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 5 | 2 | 4 | 0 | 9 | 6 | 10 | 2 | 8 |
| EPS in ₹ | 2.87 | 3.01 | -3.33 | 0.30 | -0.13 | 0.87 | 0.62 | -0.81 | -0.86 | 1.34 | 1.43 | 0.46 | 0.76 | 1.39 | 0.72 | 1.86 | 1.34 | 1.56 | 1.52 | 2.29 | 2.15 | 2.93 | 1.85 | 2.24 | 0.83 | 5.36 | 3.71 | 6.47 | 1.88 | 4.97 |
Kilitch Drugs
Kilitch Drugs
335.20
-1.95
(-0.58%)
Market Cap
585.96 Cr
PE Ratio
22.66
Volume
10,580.00
Day High - Low
341.80 - 330.00
52W High-Low
500.00 - 293.53
Key Fundamentals
Market Cap
585.96 Cr
EPS
16.60
PE Ratio
22.66
PB Ratio
2.23
Book Value
151.97
EBITDA
42.60
Dividend Yield
0.00 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
12.44
Debt to Equity
0.21
Analyst Rating and Forecast
- By Refinitiv from1 analysts
Actual
Company News
View All News
Kilitch Drugs Reports No Deviation in Rights Issue Fund Utilization for Q2 FY26Nov 15, 2025
Kilitch Drugs (India) Limited's monitoring agency report for the quarter ended September 30, 2025, confirms no deviation in the utilization of Rs. 49.92 crore raised through rights issue. The company utilized Rs. 18.30 crore towards its Greenfield project at Pen, Maharashtra, and Rs. 0.61 crore for general corporate purposes, with remaining funds invested in fixed deposits.
Kilitch Drugs Reports 18% Jump in H1FY26 Profit to ₹10.30 CroreNov 14, 2025
Kilitch Drugs Limited announced an 18.1% increase in Profit After Tax to ₹10.30 crore for H1FY26, up from ₹8.72 crore in H1FY25, driven by improved operational efficiencies and better product mix. The pharmaceutical company also reported 14.23% growth in total income to ₹101.28 crore and completed a rights issue of ₹49.92 lakh to fund its upcoming Greenfield project at Pen.
Kilitch Drugs (India) Limited reported standalone net loss of Rs. 5.27 per share for the quarter ended September 30, 2025, while successfully completing a rights issue of Rs. 4,992.51 lakhs primarily for funding capital expenditure at their Greenfield Project. The pharmaceutical company's board approved both standalone and consolidated unaudited financial results, with consolidated operations showing net profit of Rs. 4.97 per share for the same period.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,729.90 | #1 4,15,060.96 | 40.31 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 44.32 | |
6,616.50 | 1,75,647.29 | 70.47 | 9,712.00 | 18.67 | 2,191 | 35.10 | 60.68 | |
3,963.40 | 1,34,139.47 | 63.66 | 11,539.40 | 6.99 | 1,911 | 30.46 | 61.70 | |
1,465.70 | 1,18,395.11 | 21.71 | 28,409.50 | 7.12 | 5,291 | 3.71 | 38.82 | |
1,210.10 | 1,00,998.62 | #1 17.57 | 33,741.20 | 16.73 | 5,725 | -0.38 | 31.03 | |
2,182.20 | 99,682.64 | 23.02 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 63.83 | |
2,200.80 | 90,850.14 | 52.52 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 48.57 | |
894.90 | 90,047.88 | 18.16 | 23,511.00 | 18.55 | 4,615 | 34.60 | 35.88 | |
1,198.70 | 69,620.69 | 20.49 | 32,345.60 | 9.43 | 3,484 | 3.81 | 48.80 | |
5,799.00 | 69,335.74 | 28.76 | 13,458.30 | 3.70 | 2,216 | 10.98 | 63.14 |
Growth Rate
Revenue Growth
31.84 %
Net Income Growth
83.09 %
Cash Flow Change
1,246.41 %
ROE
60.93 %
ROCE
20.31 %
EBITDA Margin (Avg.)
12.87 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 |
| Fixed Assets | 9 | 42 | 33 | 33 | 32 | 32 | 30 | 65 | 64 | 62 | 64 |
| Current Assets | 47 | 47 | 49 | 63 | 65 | 56 | 80 | 114 | 126 | 146 | 174 |
| Capital Work in Progress | 0 | 0 | 1 | 3 | 20 | 30 | 66 | 3 | 4 | 6 | 47 |
| Investments | 25 | 23 | 53 | 56 | 53 | 52 | 60 | 71 | 62 | 72 | 72 |
| Other Assets | 93 | 51 | 26 | 35 | 38 | 30 | 47 | 71 | 90 | 100 | 129 |
| Total Liabilities | 127 | 117 | 113 | 128 | 144 | 143 | 203 | 210 | 220 | 240 | 313 |
| Current Liabilities | 7 | 8 | 12 | 15 | 20 | 22 | 73 | 69 | 69 | 64 | 84 |
| Non Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 28 |
| Total Equity | 120 | 109 | 101 | 113 | 123 | 121 | 130 | 140 | 151 | 176 | 201 |
| Reserve & Surplus | 107 | 96 | 88 | 96 | 106 | 103 | 112 | 121 | 131 | 160 | 186 |
| Share Capital | 13 | 13 | 13 | 14 | 15 | 15 | 16 | 16 | 16 | 16 | 16 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -39 | -2 | -0 | 3 | 3 | -5 | 10 | -2 | 10 | -1 | -9 |
| Investing Activities | -31 | -20 | -2 | -4 | -14 | -10 | -38 | -15 | 8 | -8 | -40 |
| Operating Activities | -8 | 17 | 1 | 1 | 0 | 5 | 46 | 6 | 3 | -2 | 18 |
| Financing Activities | -0 | 0 | 0 | 6 | 17 | 1 | 2 | 7 | -1 | 9 | 13 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 68.63 % | 68.33 % | 68.33 % | 68.25 % | 68.25 % | 68.25 % | 68.25 % | 68.25 % | 68.25 % | 68.25 % | 69.23 % | 69.23 % | 69.23 % | 69.23 % | 69.23 % | 69.23 % | 69.23 % | 69.23 % | 63.77 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 27.65 % | 27.41 % | 27.67 % | 27.28 % | 27.58 % | 27.73 % | 27.60 % | 27.52 % | 27.49 % | 27.40 % | 26.13 % | 26.13 % | 25.37 % | 25.21 % | 25.10 % | 25.74 % | 25.57 % | 25.54 % | 30.22 % |
| Others | 3.72 % | 4.26 % | 3.99 % | 4.48 % | 4.17 % | 4.02 % | 4.15 % | 4.23 % | 4.27 % | 4.36 % | 4.63 % | 4.64 % | 5.39 % | 5.56 % | 5.67 % | 5.02 % | 5.20 % | 5.23 % | 6.01 % |
| No of Share Holders | 9,756 | 9,214 | 8,740 | 9,129 | 9,133 | 9,209 | 9,380 | 9,435 | 9,522 | 9,573 | 9,002 | 9,062 | 9,525 | 9,620 | 9,920 | 10,139 | 9,749 | 10,379 | 10,929 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.5 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.61 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 27 Sept 2024 |  Annual General Meeting | NA | 27 Sept 2024 | 333.46 | 352.79 |
| 12 Nov 2024 |  Quarterly Result Announcement | NA | 12 Nov 2024 | 314.76 | 295.29 |
| 11 Feb 2025 | Quarterly Result Announcement | NA | 11 Feb 2025 | 307.77 | 314.33 |
| 19 May 2025 | Quarterly Result Announcement | NA | 19 May 2025 | 404.17 | 420.95 |
| 15 Jul 2025 |  Rights | 2:23 | 15 Jul 2025 | 413.30 | 477.06 |
| 13 Aug 2025 | Quarterly Result Announcement | NA | 13 Aug 2025 | 443.00 | 450.00 |
| 26 Sept 2025 | Annual General Meeting | NA | 26 Sept 2025 | 339.30 | 345.15 |
| 13 Nov 2025 | Quarterly Result Announcement | NA | 13 Nov 2025 | 380.50 | 370.45 |
Announcements
Closure of Trading Window
Dec 27, 2025
Dec 27, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 15, 2025
Nov 15, 2025Monitoring Agency ReportNov 14, 2025
Nov 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 14, 2025
Nov 14, 2025Board Meeting Outcome for Outcome Of Board MeetingNov 13, 2025
Nov 13, 2025Unaudited Financial Results For The Quarter Ended 30Th September 2025Nov 13, 2025
Nov 13, 2025Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Statement Of The Company For The Quarter Ended 30Th September 2025Nov 08, 2025
Nov 08, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 14, 2025
Oct 14, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 27, 2025
Sep 27, 2025Closure of Trading WindowSep 26, 2025
Sep 26, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 26, 2025
Sep 26, 2025Letter To Shareholders - Annual Report For FY 2024-25Sep 05, 2025
Sep 05, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2025
Sep 03, 2025Book Closure IntimationSep 01, 2025
Sep 01, 2025Notice Of Annual General MeetingSep 01, 2025
Sep 01, 2025Reg. 34 (1) Annual Report.Sep 01, 2025
Sep 01, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 26, 2025
Aug 26, 2025Postponement Of Credit Of Right Issue And Listing Of SharesAug 25, 2025
Aug 25, 2025Board Meeting Outcome for Outcome Of Board MeetingAug 25, 2025
Aug 25, 2025Postponement In Finalization Of Basis Of Allotment And Allotment Schedule For Rights IssueAug 22, 2025
Aug 22, 2025Financial Results For Quarter Ended 30Th June 2025Aug 13, 2025
Aug 13, 2025Board Meeting Outcome for Outcome Of Board MeetingAug 13, 2025
Aug 13, 2025Board Meeting Intimation for Consideration And Approval Of Unaudited Financial ResultsAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 18, 2025
Jul 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 15, 2025
Jul 15, 2025Corporate Action-Outcome of Right issueJul 12, 2025
Jul 12, 2025Corrigendum To Outcome Of Board Meeting Held On July 12 2025Jul 12, 2025
Jul 12, 2025Board Meeting Outcome for Outcome Of Board Meeting Scheduled To Approve Issue Period And Letter Of OfferJul 12, 2025
Jul 12, 2025Intimation Of Record DateJul 09, 2025
Jul 09, 2025Board Meeting Outcome for Outcome Of Board MeetingJul 09, 2025
Jul 09, 2025Board Meeting Outcome for Outcome Of Board MeetingJul 02, 2025
Jul 02, 2025Closure of Trading WindowJun 29, 2025
Jun 29, 2025Board Meeting Intimation for Considering And Approval Of The Proposal For Fund Raising By Way Of Issue Of Equity Shares Through Right Issue And Any Other BusinessesJun 29, 2025
Jun 29, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 22, 2025
May 22, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 21, 2025
May 21, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 21, 2025
May 21, 2025Financial ResultsMay 19, 2025
May 19, 2025Board Meeting Outcome for Outcome Of Board MeetingMay 19, 2025
May 19, 2025Board Meeting Intimation for Considering And Approving Standalone And Consolidated Quarterly Financial Results For The Period Ended 31St March 2025May 13, 2025
May 13, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 15, 2025
Apr 15, 2025Reply To Query LODR Regarding Completion Of Tenure Of Independent DirectorApr 09, 2025
Apr 09, 2025Announcement under Regulation 30 (LODR)-RetirementApr 07, 2025
Apr 07, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 14, 2025
Feb 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 12, 2025
Feb 12, 2025Integrated Filing (Financial)Feb 11, 2025
Feb 11, 2025Considered And Approved Unaudited Financial Result For December 31 2024Feb 11, 2025
Feb 11, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 04, 2025
Feb 04, 2025Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ending 31St December 2024Feb 03, 2025
Feb 03, 2025Disclosure Pursuant To Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015Jan 21, 2025
Jan 21, 2025Technical Indicators
RSI(14)
Neutral 40.24
ATR(14)
Less Volatile 12.89
STOCH(9,6)
Neutral 33.45
STOCH RSI(14)
Oversold 11.97
MACD(12,26)
Bearish -0.44
ADX(14)
Weak Trend 22.92
UO(9)
Bearish 42.70
ROC(12)
Downtrend And Accelerating -4.11
WillR(14)
Oversold -88.15
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
